MARAbio launches first blood test to detect maternal autoantibody-linked autism
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
This marks the first partnership between Pfizer and Cipla in India
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
The new facility is expected to generate 500-600 new jobs in the region
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
Subscribe To Our Newsletter & Stay Updated